Literature DB >> 15187750

Endothelin-1 decreases microvessel permeability after endothelial activation.

Gregory P Victorino1, Christopher R Newton, Brian Curran.   

Abstract

BACKGROUND: Endothelin-1 (ET-1) is a potent vasoconstrictor that is released during shock and sepsis. We hypothesized that ET-1 plays a role in the modulation of the elevated microvascular permeability state of the activated endothelium.
METHODS: Hydraulic permeability (Lp) was measured using the modified Landis micro-occlusion technique. The effect of different ET-1 doses on Lp was determined by obtaining paired measures of Lp at baseline and after the vessels were perfused with ET-1 at doses of 2.0 pg/mL (n = 6), 20 pg/mL (n = 6), 200 pg/mL (n = 6), or 2,000 pg/mL (n = 6). To evaluate the effects of ET-1 in the activated endothelium, additional vessels were perfused with either 10 micromol/L adenosine triphosphate (ATP) (n = 6) or 1 nmol/L bradykinin (n = 6). The vessels were then perfused with 200 pg/mL ET-1 followed by the final L determination.
RESULTS: ET-1 significantly decreased Lp at doses of 20 pg/mL (p = 0.03), 200 pg/mL (p = 0.03), and 2,000 pg/mL (p = 0.01). Endothelial activation with ATP and bradykinin increased Lp to 4.21 +/- 0.39 (p < 0.0001) and 2.72 +/- 0.24 (p = 0.001), respectively. ET-1 significantly decreased the Lp to 1.99 +/- 0.48 after activation with ATP (p = 0.004). ET-1 also decreased the Lp to 1.10 +/- 0.19 after activation with bradykinin (p = 0.001). Units for Lp are x10(-7) cm x s(-1) x cm H2O(-1).
CONCLUSION: In this model, ET-1 attenuated the increase in microvascular permeability that can be seen in inflamed vessels. In addition to its vasopressor function, ET-1 may be of benefit in pathophysiologic states by decreasing third-space fluid loss. This receptor-mediated function of ET-1 may be amenable to pharmacologic manipulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187750     DOI: 10.1097/01.ta.0000057228.45839.3c

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  6 in total

1.  Endothelin-1 attenuates increases in hydraulic conductivity due to platelet-activating factor via prostacyclin release.

Authors:  Elizabeth L Cureton; Aaron Strumwasser; Rita O Kwan; Kristopher C Dozier; Brian Curran; Javid Sadjadi; Gregory P Victorino
Journal:  J Appl Physiol (1985)       Date:  2010-12-23

2.  Endothelin 1 and prostacyclin attenuate increases in hydraulic permeability caused by platelet-activating factor in rats.

Authors:  Elizabeth L Cureton; Terry J Chong; Rita O Kwan; Kristopher C Dozier; Javid Sadjadi; Brian Curran; Gregory P Victorino
Journal:  Shock       Date:  2010-06       Impact factor: 3.454

3.  Intra-renal delivery of mesenchymal stem cells attenuates myocardial injury after reversal of hypertension in porcine renovascular disease.

Authors:  Alfonso Eirin; Xiang-Yang Zhu; Christopher M Ferguson; Scott M Riester; Andre J van Wijnen; Amir Lerman; Lilach O Lerman
Journal:  Stem Cell Res Ther       Date:  2015-01-19       Impact factor: 6.832

4.  MASP-1 Increases Endothelial Permeability.

Authors:  Márta L Debreczeni; Zsuzsanna Németh; Erika Kajdácsi; Endre Schwaner; Veronika Makó; András Masszi; Zoltán Doleschall; János Rigó; Fruzsina R Walter; Mária A Deli; Gábor Pál; József Dobó; Péter Gál; László Cervenak
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

5.  Bardoxolone Methyl Displays Detrimental Effects on Endothelial Bioenergetics, Suppresses Endothelial ET-1 Release, and Increases Endothelial Permeability in Human Microvascular Endothelium.

Authors:  Ewa Szczesny-Malysiak; Marta Stojak; Roberto Campagna; Marek Grosicki; Marek Jamrozik; Patrycja Kaczara; Stefan Chlopicki
Journal:  Oxid Med Cell Longev       Date:  2020-10-14       Impact factor: 6.543

Review 6.  Molecular Dambusters: What Is Behind Hyperpermeability in Bradykinin-Mediated Angioedema?

Authors:  Márta L Debreczeni; Zsuzsanna Németh; Erika Kajdácsi; Henriette Farkas; László Cervenak
Journal:  Clin Rev Allergy Immunol       Date:  2021-03-16       Impact factor: 8.667

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.